Stock Scorecard



Stock Summary for Astrazeneca plc (AZN) - $71.13 as of 7/14/2025 2:53:25 PM EST

Total Score

13 out of 30

Safety Score

68 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AZN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AZN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AZN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AZN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AZN (68 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 4
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 6
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for AZN

DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - 3D Sys ( NYSE:DDD ) , Rocket Pharmaceuticals ( NASDAQ:RCKT ) 7/14/2025 4:00:00 PM
Ascentage Pharma Announces Pricing of Top-Up Placement 7/14/2025 2:35:00 PM
Ascentage Pharma Announces Pricing of Top-Up Placement 7/14/2025 2:35:00 PM
Ascentage Pharma Announces Pricing of Top-Up Placement - Ascentage Pharma Group ( NASDAQ:AAPG ) 7/14/2025 2:35:00 PM
Here's Why Astrazeneca ( AZN ) is a Strong Value Stock 7/14/2025 1:40:00 PM
AstraZeneca's Drug Shows Promise for Resistant Hypertension - AstraZeneca ( NASDAQ:AZN ) 7/14/2025 1:05:00 PM
Ascentage Pharma Announces Proposed Top-Up Placement 7/14/2025 9:23:00 AM
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, PepGen, Reckitt, and Tempus and Encourages Investors to Contact the Firm - Reckitt Benckiser Group ( OTC:RBGLY ) , PepGen ( NASDAQ:PEPG ) 7/12/2025 7:12:00 PM
's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Intuit ( NASDAQ:INTU ) , AstraZeneca ( NASDAQ:AZN ) 7/12/2025 1:01:00 PM
Cathie Wood Vs. Jim Cramer: TV Host Says Top Ark AI Pick 'Losing Money Hand Over Fist' - Tempus AI ( NASDAQ:TEM ) 7/10/2025 7:31:00 PM

Financial Details for AZN

Company Overview

Ticker AZN
Company Name Astrazeneca plc
Country USA
Description AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date 7/29/2025

Stock Price History

Last Day Price 71.13
Price 4 Years Ago 53.75
Last Day Price Updated 7/14/2025 2:53:25 PM EST
Last Day Volume 2,729,868
Average Daily Volume 4,142,743
52-Week High 86.46
52-Week Low 61.24
Last Price to 52 Week Low 16.15%

Valuation Measures

Trailing PE 28.84
Industry PE 22.40
Sector PE 41.70
5-Year Average PE 30.10
Free Cash Flow Ratio 42.09
Industry Free Cash Flow Ratio 18.02
Sector Free Cash Flow Ratio 33.25
Current Ratio Most Recent Quarter 0.90
Total Cash Per Share 1.69
Book Value Per Share Most Recent Quarter 26.48
Price to Book Ratio 5.35
Industry Price to Book Ratio 34.60
Sector Price to Book Ratio 31.09
Price to Sales Ratio Twelve Trailing Months 4.05
Industry Price to Sales Ratio Twelve Trailing Months 120.05
Sector Price to Sales Ratio Twelve Trailing Months 35.30
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 3,100,460,000
Market Capitalization 220,535,719,800
Institutional Ownership 17.08%

Dividends

Ex-Dividend Date 2/21/2025
Previous Dividend Amount 0.5000
Current Dividend Amount 1.0500
Total Years Dividend Increasing 1
Trailing Annual Dividend Rate 1.55
Trailing Annual Dividend Yield 2.18%
Forward Annual Dividend Rate 2.10
Forward Annual Dividend Yield 2.95%
5-Year Dividend Payments Count 10
3-Year Average Dividend Yield 2.30%
5-Year Average Dividend Yield 2.35%
1-Year Dividend Growth Rate Percentage 41.41%
3-Year Dividend Growth Rate Percentage 18.92%
5-Year Dividend Growth Rate Percentage 10.67%
All-Time Dividend Growth Rate Percentage 5.89%
Dividend Payout Ratio 62.25%

Income Statement

Quarterly Earnings Growth YOY 33.60%
Annual Earnings Growth 18.14%
Reported EPS 12 Trailing Months 2.49
Reported EPS Past Year 0.93
Reported EPS Prior Year 3.52
Net Income Twelve Trailing Months 7,772,000,000
Net Income Past Year 7,035,000,000
Net Income Prior Year 5,955,000,000
Quarterly Revenue Growth YOY 7.20%
5-Year Revenue Growth 17.27%
Operating Margin Twelve Trailing Months 27.90%

Balance Sheet

Total Cash Most Recent Quarter 5,230,000,000
Total Cash Past Year 5,488,000,000
Total Cash Prior Year 5,840,000,000
Net Cash Position Most Recent Quarter -21,462,000,000
Net Cash Position Past Year -21,018,000,000
Long Term Debt Past Year 26,506,000,000
Long Term Debt Prior Year 22,365,000,000
Total Debt Most Recent Quarter 26,692,000,000
Equity to Debt Ratio Past Year 0.61
Equity to Debt Ratio Most Recent Quarter 0.61
Total Stockholder Equity Past Year 40,786,000,000
Total Stockholder Equity Prior Year 39,143,000,000
Total Stockholder Equity Most Recent Quarter 41,039,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 9,138,000,000
Free Cash Flow Per Share Twelve Trailing Months 2.95
Free Cash Flow Past Year 7,275,000,000
Free Cash Flow Prior Year 6,567,000,000

Options

Put/Call Ratio 0.13
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.25
MACD Signal -0.19
20-Day Bollinger Lower Band 65.08
20-Day Bollinger Middle Band 71.62
20-Day Bollinger Upper Band 78.16
Beta 0.17
RSI 54.48
50-Day SMA 72.13
150-Day SMA 67.82
200-Day SMA 65.27

System

Modified 7/11/2025 6:19:45 PM EST